Design, synthesis, and biological activity of prazosin-related antagonists. Role of the piperazine and furan units of prazosin on the selectivity for α1-adrenoreceptor subtypes

Journal of Medicinal Chemistry

Volumn 41, Issue 24, 1998, Pages 4844-4853

  Bolognesi, Maria L ^a   Budriesi, Roberta ^a   Chiarini, Alberto ^a   Poggesi, Elena ^b   Leonardi, Amedeo ^b   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Recordati SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTAZOSIN; PRAZOSIN; QUINAZOLINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; CHO CELL; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; SPLEEN; STRUCTURE ACTIVITY RELATION; VAS DEFERENS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AORTA, THORACIC; CHO CELLS; CRICETINAE; DRUG DESIGN; FURANS; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; PIPERAZINES; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 0032548074     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9810654     Document Type: Article

References (43)

1. (a) Bylund, D. B.; Eikenberg, D. C.; Hieble, J. P.; Langer, S. Z. Lefkowitz, R. J.; Minneman, K. P.; Molinoff, P. B.; Ruffolo, R. R., Jr.; Trendelenburg, U. IV. International union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 1994, 46, 121-136.
2. 1-adrenoceptors: consensus update. Pharmacol. Rev. 1995, 47, 267-270.
3. 1-adrenoceptor classification. Eur. J. Pharmacol. (Mol. Pharmacol. Section) 1994, 268, 141-149.
4. 1-Adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol. Sci. 1994, 15, 167-170.
5. Testa, R.; Guarneri, L.; Angelico, P.; Poggesi, E.; Taddei, C.; Sironi, G.; Colombo, D.; Sulpizio, A. C.; Naselsky, D. P.; Hieble, J. P.; Leonardi, A. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpka-1L adrenoceptor in tissue selectivity, Part II. J. Pharmacol. Exp. Ther. 1997, 281, 1284-1293.
6. 1A-subtype in rat submaxillary gland. Br. J. Pharmacol. 1989, 98, 883-889.
7. 1-subtype. Eur. J. Pharmacol. (Mol. Pharmacol. Section) 1995, 289, 81-86.
8. 1A-adrenoceptors. Eur. J. Pharmacol. 1991, 202, 33-44.
9. 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur. J. Pharmacol 1993, 249, 307-315.
10. 2+ in smooth muscle. Nature 1987, 329, 333-335.
11. 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br. J. Pharmacol. 1993, 109, 80-87.
12. 1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta. Life Sci. 1995, 57, PL 159-163.
13. (a) Kenny, B.; Ballard, S.; Blagg, J.; Fox, D. Pharmacological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. 1997, 40, 1293-1315.
14. 1-Adrenoceptors: subtype- and organ-selectivity of different agents. In Perspective in Receptor Research; Giardinà, D., Piergentili, A., Pigini, M., Eds.; Elsevier: Amsterdam, 1996; pp 135-152.
15. (c) Ruffolo, R. R., Jr.; Bondinell, W.; Hieble, J. P. α- and β-Adrenoceptors. From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem. 1995, 38, 3681-3716.
16. 1-adrenoceptors and native tissues. Mol. Pharmacol 1995, 48, 250-258.
17. Testa, R.; Guarneri, L.; Taddei, C.; Poggesi, E.; Angelico, P.; Sartani, A.; Leonardi, A.; Gofrit, O. N.; Meretyk, S.; Gaine, M. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J. Pharmacol. Exp. Ther. 1996, 277, 1237-1246.
18. 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol. 1996, 49, 209-215.
19. 1A-adrenoreceptor antagonist. J. Med. Chem. 1996, 39, 2253-2258.
20. 1B-adrenoceptor antagonist. J. Med. Chem. 1996, 39, 4602-4607.
21. 1b adrenergic receptor antagonist. J. Med. Chem. 1998, 47, 1205-1208.
22. 1-adrenoceptor. Eur J. Pharmacol. 1995, 272, R5-R6.
23. 1D-adrenoceptor antagonist. Bioorg. Med. Chem. Lett. 1998, 8, 1353-1358.
24. 1-adrenoreceptor blocking activity. J. Med. Chem. 1989, 32, 50-55.
25. Giardinà, D.; Gulini, U.; Massi, M.; Piloni, M. G.; Pompei, P.; Rafaiani, G.; Melchiorre, C. Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on α-blocking activity. J. Med. Chem. 1993, 36, 690-698.
26. Melchiorre, C. Tetramine disulfides: a new tool in α-adrenergic pharmacology. Trends Pharmacol. Sci. 1981, 2, 209-211.
27. Giardinà, D.; Crucianelli, M.; Marucci, G.; Melchiorre, C.; Polidori, C.; Pompei, P.; Massi, M. Pharmacological evaluation of prazosin- and doxazosin-related compounds with modified piperazine ring. Arzneim.-Forsch. / Drug Res. 1996, 46(II), 1054-1059.
28. El Hajj, T.; Masrona, A.; Martin, J. C.; Descotes, G. Synthesis of 5-(hydroxymethyl)furan-2-carboxaldehyde and its derivative by acid treatment of sugars on ion-exchange resins. Bull. Soc. Chim. Fr. 1987, 855-860.
29. Devinsky, F.; Lacko, I.; Krasnec, L. A convenient synthesis of secondary N,N'-dimethylalkanediamines. Synthesis 1980, 303-305.
30. 1A-adrenoreceptors. Eur. J. Pharmacol. 1991, 202, 33-44.
31. 1D-adrenoreceptor antagonist, isolated from Fissistigma glaucescens. Br. J. Pharmacol. 1994, 112, 1174-1180.
32. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
33. 2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 1979, 25, 637-654.
34. Van Rossum, J. M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. 1963, 143, 299-330.
35. 1-adrenoceptor antagonist. Pharmacol. Commun. 1995, 6, 79-86.
36. 1A receptor. J. Biol. Chem. 1989, 284, 14848-14852.
37. 1A receptor. Nature 1988, 335, 358-360.
38. 1-adrenoreceptors: neutral or negative antagonism? II Farmaco 1998, 53, 278-286.
39. Leff, P. The two-state model of receptor activation. Trends Pharmacol. Sci. 1995, 16, 89-97.
40. Noguera, M. A.; Ivorra, I. D.; D'Ocon, P. Functional evidence of inverse agonism in vascular smooth muscle. Br. J. Pharmacol. 1996, 119, 158-164.
41. Tallarida, R. J.; Murray, R. B. Manual of pharmacologic calculations with computer programs. Springer-Verlag: New York, 1991; Version 2.
42. De Lean, A.; Munson, P. J.; Rodbard, D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radio-ligand assay, and physiological dose-response curves. Am. J. Physiol. 1978, 235, E97-E102.
43. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.